Tandem Diabetes Care's earnings call for the third quarter of 2025 reflected significant achievements, including record sales and margin improvements, driven by strategic initiatives in pricing, product innovation, and pharmacy expansion. However, challenges remain in the form of competitive pressures on new pump starts and transition-related impacts in Europe. Overall, the highlights significantly outweigh the lowlights, suggesting a strong positive outlook.

Company Guidance

During the Tandem Diabetes Care Third Quarter 2025 Earnings Conference Call, guidance was provided on several key metrics and strategic initiatives. The company reported record third-quarter sales of $249 million, driven by ASP increases and favorable foreign currency dynamics. In the U.S., sales reached approximately $176 million, with a significant portion attributed to pricing, which alone contributed 5% growth in Q3. International sales amounted to $74 million, with end-user pump placements growing double digits year-over-year. The company achieved a gross margin of 54%, a 3 percentage point increase from the previous year. Tandem is on track to achieve $1 billion in worldwide sales for 2025, with U.S. sales expected to be around $700 million and international sales approximately $300 million. The company anticipates gross margins in the range of 53% to 54% for the year, with Q4 expected to set an all-time high in the mid- to high 50s. Adjusted EBITDA is projected to be negative 5% of sales, with further improvements anticipated in 2026 due to new product introductions, pharmacy access expansion, and operational efficiencies.

Record Third Quarter Sales

Tandem Diabetes achieved record third quarter sales with revenue of $249 million, driven by ASP increases and favorable foreign currency dynamics.

U.S. Sales Performance

U.S. sales reached approximately $176 million, marked as the highest third quarter and second highest quarter ever, primarily due to pricing improvements.

International Sales Growth

International sales achieved $74 million, delivering another record third quarter with double-digit growth in end-user pump placements.

Gross Margin Improvement

Gross margin increased by approximately 3 percentage points year-over-year to 54%, with Q4 expected to reach an all-time high in the mid- to high 50s.

Pharmacy Channel Expansion

Successfully increased pharmacy benefit coverage for Tandem Mobi to more than 40% of U.S. lives, with significant internal efforts to operationalize pharmacy access.

Launch of New Products

Announced the full availability of t:slim X2 with Abbott's FreeStyle Libre 3 Plus integration in the U.S. and expanded Type 2 commercial efforts for Control-IQ+.

Tandem Diabetes Care (DE:TD5A) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DE:TD5A Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 25, 2026	2025 (Q4)	-0.06 / -	0.009	―	―	―
Nov 06, 2025	2025 (Q3)	-0.28 / -0.27	-0.303	10.57% (+0.03)	―
Aug 06, 2025	2025 (Q2)	-0.34 / -0.42	-0.406	-2.55% (-0.01)
Apr 30, 2025	2025 (Q1)	-0.52 / -0.58	-0.562	-2.92% (-0.02)
Feb 26, 2025	2024 (Q4)	-0.18 / <0.01	-0.398	102.17% (+0.41)
Nov 06, 2024	2024 (Q3)	-0.35 / -0.30	-0.441	31.37% (+0.14)
Aug 01, 2024	2024 (Q2)	-0.46 / -0.41	-0.475	14.55% (+0.07)
May 02, 2024	2024 (Q1)	-0.65 / -0.56	-1.66	66.15% (+1.10)
Feb 21, 2024	2023 (Q4)	-0.23 / -0.40	-0.216	-84.00% (-0.18)
Nov 01, 2023	2023 (Q3)	-0.42 / -0.44	-0.657	32.89% (+0.22)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DE:TD5A Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	€13.02	€13.02	0.00%
Apr 30, 2025	€14.61	€17.54	+20.02%
Feb 26, 2025	€31.58	€24.77	-21.56%
Nov 06, 2024	€30.62	€31.60	+3.20%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.